---
pmid: '19376117'
title: HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated
  proteasomal degradation.
authors:
- Yang J
- Hong Y
- Wang W
- Wu W
- Chi Y
- Zong H
- Kong X
- Wei Y
- Yun X
- Cheng C
- Chen K
- Gu J
journal: FEBS Lett
year: '2009'
full_text_available: false
doi: 10.1016/j.febslet.2009.04.011
---

# HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal degradation.
**Authors:** Yang J, Hong Y, Wang W, Wu W, Chi Y, Zong H, Kong X, Wei Y, Yun X, Cheng C, Chen K, Gu J
**Journal:** FEBS Lett (2009)
**DOI:** [10.1016/j.febslet.2009.04.011](https://doi.org/10.1016/j.febslet.2009.04.011)

## Abstract

1. FEBS Lett. 2009 May 6;583(9):1409-14. doi: 10.1016/j.febslet.2009.04.011. Epub
 2009 Apr 18.

HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated 
proteasomal degradation.

Yang J(1), Hong Y, Wang W, Wu W, Chi Y, Zong H, Kong X, Wei Y, Yun X, Cheng C, 
Chen K, Gu J.

Author information:
(1)Gene Research Center, Shanghai Medical College, Fudan University, Box 103, 
No. 138 Yi Xue Yuan Road, Shanghai 200032, PR China.

BCL2L12 has been found to be associated with favorable prognosis in breast 
cancer patients while correlated with tumorigenesis of glioblastoma and colon 
cancer. Here, we report that BCL2L12 and its transcript variant BCL2L12A are 
degraded through ubiquitin-proteasome system (UPS). Interestingly, the 
ubiquitinations and degradations of BCL2L12 and BCL2L12A are independent of the 
internal lysine residues but the first N-terminal residues. In addition, HSP70 
was identified to interact with BCL2L12 and BCL2L12A and protected them from 
ubiquitinations and degradations in mammalian cells. In summary, HSP70 protects 
BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal 
degradation.

DOI: 10.1016/j.febslet.2009.04.011
PMID: 19376117 [Indexed for MEDLINE]
